mathew lazarus

@mlazaru

dad, trader, investor

Vrijeme pridruživanja: svibanj 2009.

Tweetovi

Blokirali ste korisnika/cu @mlazaru

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mlazaru

  1. 30. sij

    This is a material De-Risking event. Next up Unituxin read out, fingers crossed! - biotech with free cash flow, mis understood generic cliff. Ralinepag best in class asset on the come, and remodulin franchise remains intact. Orenitram and Tyvaso growing

    Poništi
  2. 29. sij

    DalcA EAHAD abstract. Zero EV for big market opportunity in Hem. no neutralizing antibodies. More to come in compliment. called out at as area or excitement. I repeat ZERO EV in DalcA program

    Poništi
  3. 24. sij

    This makes complete sense. Long Jet Blue! Great interview, worth the 2 minutes to watch. On valuation Jet Blue is accretive to as well. Great interview Joseph Denardi!

    Poništi
  4. 16. sij
    Poništi
  5. proslijedio/la je Tweet
    14. sij

    and ImmunityBio; Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted NK Cells Combined with N-803 IL-15 Fusion Protein

    Poništi
  6. 14. sij

    - "Based on these encouraging findings, we plan to initiate clinical trials to confirm efficacy in second-line metastatic pancreatic cancer and third-line Triple Negative Breast cancer.”

    Poništi
  7. 14. sij

    - triangle offense: patients live longer on NK cell

    Poništi
  8. 12. sij

    "We believe ADVM-022 has the potential to be a paradigm-changing treatment for patients with wet AMD and for patients with diabetic retinopathy" gene therapy cures

    Poništi
  9. 11. sij
    Poništi
  10. proslijedio/la je Tweet

    2016: Patrick Soon-Shiong vows to transform cancer treatment by 2020 2020: Not much has happened, as reports after digging into PSS’s cancer efforts. Great story:

    Poništi
  11. 7. sij
    Poništi
  12. proslijedio/la je Tweet
    17. pro 2019.
    Odgovor korisniku/ci

    The combo preclinical data show promise. DREAMM-5 may be their ticket here.

    Poništi
  13. 16. pro 2019.

    - the big winner from todays BCMA data. Combo Trial planned. Gamma Secretase Inhibitor enhances activity......

    Poništi
  14. 16. pro 2019.

    -3rd w CR?!"2 out of 9 patients to date have ongoing complete responses with durations ranging from 8 to 11 months, with a 3rd patient demonstrating a partial response (near complete response) in the target lesion after initiation of targeted and endocrine therapy offstudy"

    Poništi
  15. proslijedio/la je Tweet

    Join us for a discussion of head gear on ⁦ Pregame! ⁦⁩ ⁦

    Poništi
  16. 14. pro 2019.

    - poster from San Antonio: 78% Disease Control Rate(DCR) , 22% Complete Responder (CR), 67%(ORR)! -

    Poništi
  17. proslijedio/la je Tweet
    9. pro 2019.

    We are pleased to announce updated clinical data on MB-107 lentiviral gene therapy for presented at by and

    Poništi
  18. 9. pro 2019.

    - your spaceship is about to blast off.... HiHOHiHOHiHO:

    Poništi
  19. proslijedio/la je Tweet
    9. pro 2019.

    Lp(a) Major Risk Factor for Heart Disease. Big news out of deCODE regarding Lp(a). Directly relevant to 's AMG 890, that targets Lp(a), licensed to . Must be leading up to something big coming out soon.

    Poništi
  20. 6. pro 2019.

    - dear market, take a look at this abstract, will be presented at San Antonio next week. Triple Negative Breast Cancer data: Too good to ignore,

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·